[eng] Idiopathic pulmonary fibrosis (IPF) is a highly mortal, chronic, and irreversible lung
disease characterized by inflammation and structural abnormalities of the tissue leading
to progressive pulmonary fibrosis. Approximately 3 million people worldwide suffer from
this condition and only two pharmacological treatments are approved: pirfenidone and
nintedanib. These drugs slow IPF progression but do not cure it. Due to this, mesenchymal
stem cells (MSCs) are being explored as therapeutic agents for IPF because they are
multipotent cells with potent regenerative and immunomodulatory capacities that could
ameliorate fibrosis effects. MSCs in the form of 3D spheroids, which are denominated as
“biospheres” (BS), have shown improved in vivo post-grafting survival rates and other
advantages in comparison to traditional 2D suspension MSCs. This Master Thesis is based
on the hypothesis that mesenchymal stem cells in the form of BS might be an improved
therapeutic approach to treat IPF. The objective of this project was to define the basis of
an experimental animal model for IPF with bleomycin (BLM) induced lung fibrosis in
Swiss Nude Mice Crl:NU(Ico)-Foxn1nu with a treatment with human umbilical cord
MSCs (UC-MSCs) in suspension and biosphere presentation. Results showed a clear
tendency for MSCs treated groups, in special BS MSCs, to present ameliorated fibrosis
effects in response to BLM-induced lung injury. On a cellular level, there was evidence
of human mitochondria from the grafted stem cells at an intracellular level in lung
epithelium. On a histopathological level, biosphere treated animals showed the lower
Ashcroft scores. On a molecular level, BLM+Biospheres treated mice showed higher
levels of mitochondrial DNA than MSCs in suspension form. Finally, BLM+BS treated
mice showed the lowest concentrations of leukocytes which could be inferred to lower
inflammation.